Cancer immunotherapy: A insight into future perspectives

Research and Markets have announced the addition of the Future perspectives in cancer immunotherapy Report to their offering

(PRWEB) November 6, 2003 --"Future perspectives in cancer immunotherapy" is a summarized version of our more extensive report "A Shift in Cancer Immunotherapy Strategies?". Still, it provides the essence and main conclusive parts and will work as a guideline for trend analysis, even though the bulk of data which included in the larger report has been removed. If your primary interest is to read the more conclusive and analytical parts, this report is an excellent choice. It provides a broad overview of current efforts in cancer immunotherapy R&D as well as concludes and assesses major factors important for success. Further, it describes the ongoing efforts in developing innovative immunotherapies for the treatment of cancer. Trends within the industry are identified and analyzed.

The contents of this report is structured into several well-defined therapeutic concepts. This includes major therapeutic strategies such as monoclonal antibodies, anti-idiotypic antibodies, tumor antigens, cellular vaccines, gene therapy, immunostimulatory drugs and other biological drugs. The comparison of therapeutic strategies, targets and cancer indications reveals differences between disease and treatment.

The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way. One example is Rituxan, a "drug" that has seen its revenue grow from $152 million in 1998 to more than $1 billion in 2002. Other immune-based therapies that have already reached the market is Zevailn, Bexxar, Campath, OncoVax and Erbitux.

Other cancer vaccine strategies that are on the way are Actimmune, Allovectin-7, Avicine, BEC2, Canvaxin, CeaVac, Gastrimmune, GMK, LymphoCide, Melacine, Ovarex, Oncophage, Osidem and. These treatments are all FDA approved or in late stage clinical trails. Immunotherapy
has for some time been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy remains solid, there are still a number if missing

For a complete index of this report click on
http://www.researchandmarkets.com/reports/39354

About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.
###
For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com
or mailto:press@researchandmarkets.com